Oncolytics Biotech Announces Positive Top-Line Data from REO 018 Randomized Study of REOLYSIN

Oncolytics Biotech (NASDAQ: ONCY ) today announced positive top-line data for the endpoints in its double blinded, randomized clinical study examining REOLYSIN in combination with carboplatin and paclitaxel in patients with second-line platinum-refractory, taxane-naïve head and neck cancers (REO 018). Summary of Trial Results Efficacy An analysis was performed on an